{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multimorbidity/management/assessment/","result":{"pageContext":{"chapter":{"id":"b7aa5bb5-dec9-5ba3-a7c3-531c043c88a3","slug":"assessment","fullItemName":"Scenario: Assessment","depth":2,"htmlHeader":"<!-- begin field e394322c-fcef-40f9-b247-a8da0111079a --><h2>Scenario: Assessment</h2><!-- end field e394322c-fcef-40f9-b247-a8da0111079a -->","summary":"Covers the assessment of a patient with multimorbidities.","htmlStringContent":"<!-- begin item 1fef3aed-c36a-4e09-84d2-a8da0111079a --><!-- begin field 69a18f43-3433-4a9a-9143-acbc015afffa --><p>From age 18 years onwards.</p><!-- end field 69a18f43-3433-4a9a-9143-acbc015afffa --><!-- end item 1fef3aed-c36a-4e09-84d2-a8da0111079a -->","topic":{"id":"afb2159a-eadd-5052-97eb-1dce41f2c486","topicId":"0185ed8c-4e70-4790-a4e6-a8da0110e5d4","topicName":"Multimorbidity","slug":"multimorbidity","lastRevised":"Last revised in May 2018","chapters":[{"id":"d7e72ebc-7b1a-5e13-a5b9-00759c8b31e9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2b2c3188-0505-5fc9-8e36-8532ad72a17d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"333da584-961a-5d7b-96a7-286526c7e1d5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b89fdcc9-e350-51b1-93b6-9dc01de262a9","slug":"changes","fullItemName":"Changes"},{"id":"c6e44a1c-0884-59cf-b764-3fde162fafff","slug":"update","fullItemName":"Update"}]},{"id":"c69b0aa8-49b3-5def-a23c-170a4975145e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4374e04a-4268-514a-aa86-5cb0e133b97a","slug":"goals","fullItemName":"Goals"},{"id":"a69a675a-302f-51a4-baba-131ae79a6f2d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"76c1ef15-33ef-55ec-8020-93bae3f341f4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"3e7da2ad-6e82-59c7-98fb-782c5806d8d2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f4376f7f-a3ab-56ba-bed3-04d36b928de8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"44cb2c4f-e8e8-5eff-8520-7fe75f25f8dc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"22ce748c-e6b7-5868-b561-5739ea639fe7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"10c6dde3-7676-58b3-9648-95d982c82763","slug":"definition","fullItemName":"Definition"},{"id":"158f785a-d6d3-56af-8be3-5e7e487fb117","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bc52ca24-9c78-5d1e-84e9-21df719be766","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"5982f062-02cf-523e-9cca-f07bbbad88bd","slug":"complications","fullItemName":"Complications"}]},{"id":"9f8b6691-13c9-5699-898f-387dbcb392ef","fullItemName":"Management","slug":"management","subChapters":[{"id":"b7aa5bb5-dec9-5ba3-a7c3-531c043c88a3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"c34d9b00-c4aa-5f08-8294-722b713fd78f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"1b6e4f95-9a87-5b60-82c8-7e872e24c591","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"013747af-d248-52a6-bed4-74219e60b0be","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"35c23313-5aa9-565d-a80b-6655b4c5a629","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"affc9615-bb4f-52f3-b03c-aa9f9c1d21c0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"829eebfe-7ae3-573f-a7f5-1b7a83fa62da","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b6b832c9-c857-5c85-af54-5dd96034da3b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"09500991-a812-5959-97ea-b91a28f188d1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"14f1c0ab-238f-5baa-83f1-479a5f5fccbb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9f8b6691-13c9-5699-898f-387dbcb392ef","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"034878ed-32b5-5971-bb6b-5b7443fc8795","slug":"who-to-assess","fullItemName":"Who to assess","depth":3,"htmlHeader":"<!-- begin field 912e7b7b-ac55-429d-addd-a8da0111079a --><h3>Who should I assess for multimorbidity?</h3><!-- end field 912e7b7b-ac55-429d-addd-a8da0111079a -->","summary":null,"htmlStringContent":"<!-- begin item 515e4747-0e88-4dcd-89be-a8da0111079a --><!-- begin field 2eba5841-a5b8-4288-8ec6-a8da0111079a --><ul><li><strong>Identify people who may benefit from an approach to care that takes account of multimorbidity</strong><strong>:</strong><ul><li>Opportunistically during routine care.</li><li>Proactively using healthcare records, for example, assessing the number of regular medicines a person is prescribed. <ul><li>People taking 15 or more regular medicines are likely to be at higher risk of adverse events and drug interactions.</li></ul></li></ul></li><li><strong>Consider that people may need a multimorbidity approach, if they</strong><strong>:</strong><ul><li>Find it difficult to manage their treatments or day-to-day activities.</li><li>Receive care and support from multiple services and need additional services.</li><li>Have both long-term physical and mental health conditions.</li><li>Have frailty or are at risk of falls.</li><li>Frequently seek unplanned or emergency care.</li><li>Are prescribed 10–14 regular medicines, or are prescribed fewer than 10 regular medicines but are at particular risk of adverse events.</li></ul></li><li>Consider using a validated tool such as the Electronic Frailty Index (eFI), Predicting Emergency admissions Over the Next Year (PEONY) or <a href=\"https://clinrisk.co.uk/ClinRisk/QAdmissions.html\" data-hyperlink-id=\"e6fe4617-6328-47b4-a99b-a8f701601bb4\">QAdmissions</a> (if available in primary care electronic health records) to identify adults with multimorbidity who are at risk of adverse events, such as unplanned hospital admission or admission to care homes.<ul></ul></li></ul><!-- end field 2eba5841-a5b8-4288-8ec6-a8da0111079a --><!-- end item 515e4747-0e88-4dcd-89be-a8da0111079a -->","subChapters":[{"id":"34bb897f-b418-538a-adf3-9397a3993cc7","slug":"basis-for-recommendation-92b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5bafc302-8c13-4a88-af3b-a8da0111079a --><h4>Basis for recommendation</h4><!-- end field 5bafc302-8c13-4a88-af3b-a8da0111079a -->","summary":null,"htmlStringContent":"<!-- begin item 92bb0836-3f1f-421d-a710-a8da0111079a --><!-- begin field 0d334a0a-8ddb-4299-b585-a8da0111079a --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Multimorbidity: clinical assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">NICE, 2016</a>], and <em>Multimorbidity and polypharmacy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">NICE, 2017a</a>].</p><h5>Polypharmacy and multimorbidity</h5><ul><li>In a study of 180,815 adults in primary care approximately 20.8% of people with two medical conditions were prescribed 4–9 drugs and 1.1% were prescribed 10 or more [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">Payne, 2014</a>]. <ul><li>For people with six or more conditions, these were 47.7% and 41.7%, respectively.</li></ul></li><li>Polypharmacy is associated with an increased risk of adverse effects, drug interactions, potentially inappropriate prescribing, and reduced drug adherence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">Duerden, 2013</a>]. </li><li>Polypharmacy is often driven by the introduction of multiple medicines intended to reduce the risk of future morbidity and mortality in specific health conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">NICE, 2017a</a>]. <ul><li>However, the evidence for recommendations in NICE guidance on single health conditions is often drawn from people without multimorbidity who are participating in studies and who are taking fewer regular medicines.</li><li>The absolute benefit made by each additional medicine is likely to reduce when a person is taking multiple preventative medicines, however, the risk of harms is likely to increase with additional medicines being taken.</li></ul></li></ul><!-- end field 0d334a0a-8ddb-4299-b585-a8da0111079a --><!-- end item 92bb0836-3f1f-421d-a710-a8da0111079a -->","subChapters":[]}]},{"id":"cfac881c-de34-5644-96a6-f10163c15e3b","slug":"how-to-assess","fullItemName":"How to assess","depth":3,"htmlHeader":"<!-- begin field 560b6ec5-9dc7-4270-9691-a8db0074783a --><h3>How should I assess people with multimorbidity?</h3><!-- end field 560b6ec5-9dc7-4270-9691-a8db0074783a -->","summary":null,"htmlStringContent":"<!-- begin item d891dae9-8a2d-4b0e-9ba5-a8db00747791 --><!-- begin field 4895515b-4c76-4ef1-af69-a8db0074783a --><ul><li><strong>Establish the extent of the disease burden</strong> — ask how the health problems affect their day-to-day life. Include a discussion of:<ul><li>Mental health.</li><li>How disease burden affects their wellbeing.</li><li>How their health problems interact and how this affects quality of life.</li></ul></li><li><strong>Establish the treatment burden</strong> — ask how treatments affect their day-to-day life. Include a discussion of:<ul><li>The number and type of healthcare appointments and where these take place.</li><li>The number and type of medicines they take and how often they experience harms from medicines.</li><li>Non-pharmacological treatments such as diets, exercise programmes and psychological treatments.</li><li>Any effects of treatment on their mental health or wellbeing.</li></ul></li><li><strong>Explore the person's attitudes to their treatments and the potential benefits and harms of those treatments</strong> — follow the recommendations on patient involvement in decisions about medicines and understanding the person's knowledge, beliefs and concerns about medicines in the <a href=\"https://www.nice.org.uk/guidance/cg76\" data-hyperlink-id=\"1b92d508-1bd1-482c-9914-a8f70159beae\">NICE guideline on medicines adherence</a>.</li><li><strong>Also ask about, and consider:</strong><ul><li>Social circumstances, financial constraints, living conditions and social support.</li><li>Health literacy.</li><li>Functional autonomy.</li><li>Coping strategies.</li></ul></li><li><strong>Be alert to the possibility of:</strong><ul><li>Depression and anxiety — consider identifying, assessing and managing these conditions. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>. </li><li>Chronic pain and the need to assess this, and the adequacy of pain management.<ul></ul></li></ul></li><li><ul></ul><strong>Encourage people with multimorbidity to clarify what is important to them, including their personal goals, values and priorities </strong>— these may include:<ul><li>Maintaining their independence.</li><li>Participating in family life, work or social activities.</li><li>Preventing specific adverse outcomes (for example, stroke), reducing harms from medicines.</li><li>Reducing treatment burden.</li><li>Improving the quality and length of life.</li><li>Pain and symptom relief, including palliative care needs.</li></ul></li><li><strong>Consider assessing <a class=\"topic-reference internal-reference\" href=\"/topics/multimorbidity/management/assessment/#frailty\">frailty</a> in people with multimorbidity.</strong><ul><li>Be cautious about assessing frailty in people who are acutely unwell.</li><li>Do not use a physical performance tool to assess frailty in people who are acutely unwell.</li></ul></li><li>Clarify whether, and how, they would like their partner, family members and/or carers to be involved in key decisions about the management of their conditions and review this regularly. <ul><li>If applicable, consider preferences of informal caregivers or family.<ul></ul></li></ul></li></ul><!-- end field 4895515b-4c76-4ef1-af69-a8db0074783a --><!-- end item d891dae9-8a2d-4b0e-9ba5-a8db00747791 -->","subChapters":[{"id":"731783e7-bbd9-5073-b5d4-51fed825c046","slug":"frailty","fullItemName":"Frailty","depth":4,"htmlHeader":"<!-- begin field 9507a64d-a07f-42d5-8257-a8db00777de1 --><h4>How should I assess frailty?</h4><!-- end field 9507a64d-a07f-42d5-8257-a8db00777de1 -->","summary":null,"htmlStringContent":"<!-- begin item 70b97152-c33f-45a0-bc3b-a8db00777b93 --><!-- begin field 4f885ddd-c787-49d7-972d-a8db00777de1 --><ul><li>When assessing frailty, consider using one of the following:<ul><li><strong>An informal assessment of gait speed</strong> (for example, time taken to answer the door, time taken to walk from the waiting room).</li><li><strong>A formal assessment of gait speed</strong> — taking more than 5 seconds to walk 4 metres indicates frailty.</li><li><strong>Self-reported health status</strong> — ask the person how they would rate their health on a scale of 0–10. A score of 6 or less indicates frailty.</li><li><strong>The PRISMA-7 questionnaire</strong> — three or more positive responses to the following questions suggests the need for further clinical review:<ul><li>Are you more than 85 years old?</li><li>Are you male?</li><li>In general do you have any health problems that require you to limit your activities?</li><li>Do you need someone to help you on a regular basis?</li><li>In general, do you have any health problems that require you to stay at home?</li><li>If you need help, can you count on someone close to you?</li><li>Do you regularly use a stick, walker or wheelchair to get about?</li></ul></li></ul></li></ul><!-- end field 4f885ddd-c787-49d7-972d-a8db00777de1 --><!-- end item 70b97152-c33f-45a0-bc3b-a8db00777b93 -->","subChapters":[]},{"id":"ec8805f4-d4a9-5904-9f99-545c51c6a272","slug":"basis-for-recommendation-5bc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9015f962-e530-41eb-886b-a8db00747844 --><h4>Basis for recommendation</h4><!-- end field 9015f962-e530-41eb-886b-a8db00747844 -->","summary":null,"htmlStringContent":"<!-- begin item 5bc99d2f-bf59-44c6-a44a-a8db00747844 --><!-- begin field ee715c03-b661-4b4d-93c2-a8db00747844 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Multimorbidity: clinical assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">NICE, 2016</a>], and <em>Multimorbidity and polypharmacy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">NICE, 2017a</a>], expert opinion in <em>The Ariadne principles: how to handle multimorbidity in primary care consultations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">Muth, 2014</a>], and <em>PRISMA-7: A case-finding tool to identify older adults with moderate to severe disabilities</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">Raiche, 2008</a>].</p><h5>Assessing the treatment burden [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multimorbidity/references/\">NICE, 2017a</a>]</h5><ul><li>Problematic polypharmacy may arise if medicines are used without a good evidence base for doing so, or if (taking into account the person's views and preferences) the risk of harm from treatments is likely to outweigh the benefits, or where one or more of the following apply:<ul><li>The medicine combination is hazardous because of interactions.</li><li>The overall demands of medicine-taking, or 'pill burden', are unacceptable to the person.</li><li>These demands make it difficult to achieve clinically useful medicines adherence.</li><li>Medicines are being prescribed to treat the adverse effects of other medicines, but alternative solutions are available to reduce the number of medicines prescribed.</li></ul></li></ul><!-- end field ee715c03-b661-4b4d-93c2-a8db00747844 --><!-- end item 5bc99d2f-bf59-44c6-a44a-a8db00747844 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}